Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease

Raquel Buj and Katherine M. Aird*

Department of Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, PA, United States

The maintenance of a healthy deoxyribonucleotide triphosphate (dNTP) pool is critical for the proper replication and repair of both nuclear and mitochondrial DNA. Temporal, spatial, and ratio imbalances of the four dNTPs have been shown to have a mutagenic and cytotoxic effect. It is, therefore, essential for cell homeostasis to maintain the balance between the processes of dNTP biosynthesis and degradation. Multiple oncogenic signaling pathways, such as c-Myc, p53, and mTORC1 feed into dNTP metabolism, and there is a clear role for dNTP imbalances in cancer initiation and progression. Additionally, multiple chemotherapeutics target these pathways to inhibit nucleotide synthesis. Less is understood about the role for dNTP levels in metabolic disorders and syndromes and whether alterations in dNTP levels change cancer incidence in these patients. For instance, while deficiencies in some metabolic pathways known to play a role in nucleotide synthesis are pro-tumorogenic (e.g., p53 mutations), others confer an advantage against the onset of cancer (G6PD). More recent evidence indicates that there are changes in nucleotide metabolism in diabetes, obesity, and insulin resistance; however, whether these changes play a mechanistic role is unclear. In this review, we will address the complex network of metabolic pathways, whereby cells can fuel dNTP biosynthesis and catabolism in cancer, and we will discuss the potential role for this pathway in metabolic disease.

Keywords: purines, pyrimidines, c-Myc, p53, mTORC1, diabetes, obesity

INTRODUCTION

The maintenance of deoxyribonucleotide triphosphate (dNTP) pools is critical for multiple cellular pathways. For instance, imbalances in dNTPs are associated with genomic instability (1). Likewise, they have also been shown to disturb mitochondrial DNA (mtDNA) and consequently mitochondrial fitness, which may lead to mitochondrial diseases (MDs), such as diabetes, obesity, and cancer (2). Additionally, disorders of purine and pyrimidine metabolism (DPPM) profoundly affect cell metabolism, underlying the importance of nucleotides for cell behavior (3). Thus, both nucleotide synthesis and degradation must be exquisitely fine-tuned. In this review, we will focus on synthesis of dNTPs and the consequences of dNTP pool imbalances in cancer and MDs.

HEALTHY dNTP POOLS

A correct balance of dNTPs is necessary for the prevention of multiple pathologies. A healthy cell must maintain two asymmetric and spatial-temporal dNTP pools; one for nuclear DNA synthesis and repair and another for mtDNA replication and repair. Disruptions in dNTP balance are associated with enhanced mutagenesis, leading to genomic instability, which promotes cancer (4), and may have a role in metabolic disease (5).
Cytosolic dNTP pool concentrations positively correlate with the cell cycle. In fact, the amount of dNTPs at the beginning of S-phase is not enough for a complete DNA duplication (6). The S-phase increase in dNTPs is necessary for faithful nuclear DNA replication. mtDNA is replicated continuously in post-mitotic cells, and faithful maintenance of mtDNA also depends on correctly balanced dNTPs (7). Thus, both proliferating and non-proliferating cells need to fine-tune nucleotide and dNTP synthesis to allow for both nuclear and mtDNA replication and repair to maintain the health of the cell.

**Anabolism and Catabolism of Nucleotides**

Cells possess two biosynthetic pathways to produce dNTPs: *de novo* and salvage (8). Purines and pyrimidines arise from two different *de novo* pathways that generate nucleotides starting from raw material (glucose, glutamine, aspartate, and HCO₃⁻) (9). The *de novo* nucleotide synthesis pathway is highly energy-intensive (9). Therefore, cells have developed a more energy-efficient route to synthesize nucleotides, termed the salvage pathway (10). The salvage pathway acts as a recycling plant taking free nitrogen bases and nucleosides arising from nucleic acid breakdown and diet (9). Nucleosides are hydrophilic compounds, thus proper function of nucleoside transporters (SLC29 and SLC28 families) is an essential requirement for salvage pathway function (11). Ribonucleotides obtained by either pathway can be reduced to their deoxyribonucleotide counterparts in a reaction catalyzed by ribonucleotide reductase (RNR) (12).

Turnover of RNA and other nucleotides occurs regularly to maintain homeostasis. Human cells cannot break down the purine ring. Purine catabolism involves a sequence of three reactions in which nucleotides are stripped step-by-step from their phosphates and sugar to finally become oxidized to the end product uric acid (UA), which is excreted into the urine (13). Conversely, uracil and thymidine rings can be completely degraded to β-alanine and β-aminoisobutyrate, respectively. Subsequently, both metabolites can be excreted or transformed into intermediates of the tricarboxylic acid (TCA) cycle (14). Biosynthesis and catabolism of nucleotides and dNTPs are highlighted in Figure 1.

**IMPAIRED NUCLEOTIDE METABOLISM IN CANCER AND METABOLIC DISEASE**

Deregulation of nucleotide metabolism is associated with a broad spectrum of pathological conditions, including cancer and MDs (15–17). Virtually all metabolic pathways have been implicated in dNTP biosynthesis. Thus, *de novo* and salvage pathways, as well as all involved anapleurotic reactions (Figure 1), need to be highly cross-regulated.

It is well known that cancer cells must increase dNTP biosynthesis (18) to ensure rapid replication of the genome (17). This occurs through a variety of pathways (discussed below). In contrast, MDs are caused by congenital or acquired genetic defects in metabolic enzymes. DPPM are due to abnormalities in the biosynthesis, interconversion, and degradation of nucleotides (19). DPPM have a wide variety of clinical presentations, highlighting the importance of proper nucleotide metabolism for cell and organism function (15). Alterations in nucleotide metabolism are also present in other metabolic-related pathological conditions, such as diabetes, obesity, and insulin resistance (20–22) (Table 1). In this section, we will summarize some important features affecting nucleotide metabolism in cancer and MDs.

**Deregulation of Major Growth Signaling Pathways Leads to Nucleotide Pool Imbalances in Cancer and Metabolic Disease**

The main growth signaling pathways (PI3K-AKT and ERK1/2-MAPK) are induced and maintained during metabolic reprogramming of cancer (18). Additionally, deregulation of these pathways may contribute to different MDs, including diabetes, obesity, or steatosis resistance (33, 89, 90). These pathways sense and orchestrate nutrient utilization; therefore, is not surprising that alterations in these pathways affect energy and biomass production and cause a broad variety of diseases.

mTOR is a central signaling pathway that integrates environmental inputs (e.g., nutrients and hormones) into downstream pathways to control many cellular processes (91). This includes regulation of metabolism, growth, and survival (32). Indeed, the mTORC1/2 pathway not only promotes glucose uptake and protein and lipid biosynthesis, but also promotes nucleotide biosynthesis (29, 30) and uptake of nucleotides through transporters (88). At least one member of this pathway is altered in 38% of human cancer (92). Altered metabolism induced by aberrant mTORC1 activation has also been shown to play a role in diabetes and obesity (32, 93).

-c-Myc, one of the most commonly altered proteins in human cancer, is also regulated by PI3K-AKT and ERK1/2-MAPK pathways (94). c-Myc is a highly pleiotropic transcription factor considered a master regulator of cell metabolism (34, 35) through regulation of glycolysis, glutamine metabolism, and mitochondrial biogenesis (95, 96). Indeed, c-Myc has been shown to induce hepatic glucose uptake and utilization, while blocking gluconeogenesis and ketogenesis, suggesting a counteracting effect of c-Myc in obesity and insulin resistance (36, 97). In addition to regulating glucose and glutamine, substrates for purine and pyrimidine biosynthesis (Figure 1) (98), c-Myc also transcriptionally regulates nucleotide metabolic enzyme gene expression (35). Thus, deregulation in c-Myc acutely alters nucleotide homeostasis in cancer (99), and it is interesting to speculate that the role of c-Myc in MDs is also related to nucleotide metabolism.

Previous publications from our laboratory and others have shown that DNA damage and DNA damage response (DDR) proteins regulate dNTP biosynthesis in the context of cancer (80, 100, 101). Interestingly, upregulation of p53, a key player in the DDR, in adipose tissue is associated with increased inflammation and insulin resistance (102). Notably, wild-type p53 negatively regulates G6PD activity (37), the rate-limiting enzyme of the pentose phosphate pathway and one of the most important sources of nucleotides (103). Upregulation of G6PD correlates with functional defects in liver, heart, and pancreas of obese and diabetic animals (104). Although the relationship between G6PD upregulation and increased oxidative stress has been studied in MD (105), the implication for nucleotide metabolism has not
yet been addressed. More research is needed to understand the contribution of dNTP imbalances due to G6PD deregulation in diabetes and obesity.

An imbalance in nucleotides has been shown in two different studies related to diabetes (106, 107). Additionally, pyrimidine metabolism has been linked to fatty liver (26). Interestingly, increasing evidence suggests a link between obesity, a risk factor for non-alcoholic fatty liver disease (108), and cancer. Obese patients show many cancer-promoting features, such as chronic low-level inflammation (109), insulin-resistance/diabetes (110), and deregulation of mTORC1 (111). Although the contribution of deregulated nucleotide pools promoting cancer has been extensively demonstrated (18, 112–115), their role in MD and metabolic-related diseases has not yet been elucidated. Based on these recent studies, we speculate that deregulation of nucleotide pools may in part contribute to the altered metabolic landscape promoting obesity and diabetes. Studying the implications of altered nucleotide pools in these diseases would open a therapeutic window based on modulation of nucleotide metabolism.
TABLE 1 | Genes, protein families, and pathways discussed in this review: role in deoxyribonucleotide triphosphate (dNTP) metabolism and expression in cancer and metabolic disease.

| Gene/family/pathway | Known role in dNTP metabolism | Expression in cancer | Expression in metabolic disease |
|---------------------|-------------------------------|---------------------|-------------------------------|
| Purine/pyrimidine synthesis pathway | Necessary for de novo dNTP biosynthesis (8)* | Increased (23) or mutated (24, 25) | Hepatic steatosis (uridine metabolism) (L) (26) Diabetes* (j) (27) |
| MTOR | Promotes glucose uptake (28); promotes de novo nucleotide biosynthesis (29, 30) | Increased (31) | Diabetes (t) (52) Obesity (t) (53) |
| MYC | Induces glucose uptake and utilization (34); transcriptionally regulates nucleotide metabolic enzymes (23, 35) | Increased (oncogene) (23) | Insulin resistance (t) (6) Obesity (t) (58) |
| TPS3 | Negative regulator of pentose phosphate pathway through G6PD (37); gain-of-function mutations increase gene transcription of genes for dNTP synthesis (38) | Decreased or mutated (tumor suppressor) (39) | Insulin resistance (t) (5) Glucose intolerance (mut) (5) Mitochondrial changes (mut) (40) |
| PI3K-AKT pathway | Oncogenic activation promotes glucose and glutamine uptake and catabolism (41) | Increased (oncogenes) (41) | Diabetes (t) (42) Nonalcoholic fatty liver disease (t) (43) Obesity (t) (44) |
| ERK-MAPK pathway | Regulation of G1S in de novo pyrimidine synthesis (45) | Increased (oncogenes) (46) | Diabetes (t) (47) Obesity (t) (48) |
| G6PD | Rate-limiting for ribose-5-phosphate synthesis from the PPP (49)* | Increased or mutated (50) | Obesity (t) (51) Diabetes (t) (52) |
| RRM1 | Catalytic subunit of the ribonucleotide reductase (RNR); catalyzes the reduction of deoxyribonucleotides from ribonucleotides (12)* | Increased or decreased (53) | Unknown |
| RRM2 | Regulatory subunit of RNR (12); S-phase regulated (54); rate-limiting enzyme in the reduction of deoxyribonucleotides from ribonucleotides (55)* | Increased (oncogene) (53) | Unknown |
| RRM2B | Regulatory subunit of the RNR (56); formation of deoxyribonucleotides from ribonucleotides for DNA damage repair and mitochondrial DNA (mtDNA) replication (57–59)* | Increased or decreased (53) | Mitochondrial disorders (t) (60) |
| SLC25 family | Mitochondrial nucleoside transporters (61) Important for mtDNA pools through the salvage pathway (62) | Increased (63) | Mitochondrial disease (mut)* Mitochondrial dysfunction (mut) (61) |
| SLC29 and SLC28 families | Nucleoside transporters that are important for the salvage pathway (11, 64, 65) | Increased (11) | Diabetes (mut)* (66) |
| TG2 | Phosphorylates deoxycytidine to generate dCTP (67) | Unknown | Mitochondrial disease (t) (68) |
| DGUK | Catalyzes the conversion of deoxyguanosine to dGMP (67)* | Mutated (69, 70) | Mitochondrial disease (mut) (69) |
| TSNK | Mitochondrial helicase (71) | Unknown | Mitochondrial dysfunction (mut) (72, 73) |
| POLG | Catalytic subunit of the mitochondrial DNA polymerase (74) | Mutated (75–77) | Mitochondrial disease (mut) (77–79) |
| Ataxia-telangiectasia mutated | Increases glucose/glutamine uptake and inhibits the PPP (80) | Mutated (81) | Mitochondrial dysfunction (mut)* Insulin resistance (mut)* (82) |
| XOR | Catalyzes the conversion of xanthine to uric acid (83)* | Increased or decreased (64) | Metabolic syndrome (mut)* Insulin resistance (mut)* Diabetes (mut)* Fatty liver disease (mut)* (65) |

*These genes/pathways are shown in Figure 1.
†These studies show that purines and pyrimidines are downregulated in diabetes. It is not known whether changes in purine or pyrimidine synthesis genes are the mechanism behind this observation.
‡Occurs in patients with Li–Fraumeni syndrome.
§SLC25A4 (56).
∥SLC25A3 and SLC25A36 have only been tested in mouse models (67, 68).
¶SLC29A3 is the only gene in this family that has been found to affect metabolic disease.
‖While the data are limited, some patients with DGUK mutations have hepatocellular carcinoma.
¶¶Occurs in patients with ataxia-telangiectasia.
††Increased XOR expression/activity is likely important for cancer initiation; however, XOR expression is decreased in most established tumors.
‡‡Occurs in patients with XOR deficiency.

RNR in Cancer and Metabolic Disease

Ribonucleotide reductase reduces ribonucleotides to the corresponding deoxyribonucleotides (116, 117). In mammals, RNR is a tetrameric enzyme composed of two homodimeric subunits, RRM1 and RRM2. Whereas, RRM1 is continuously expressed throughout the cell-cycle, expression of RRM2 is activated upon entry into S-phase (54, 118). Additionally, RRM2 is rapidly degraded via the proteasome in G2 (12, 119). Thus, RRM2 is
considered rate-limiting for RNR activity. RRM2B (RNR subunit M2B) is an alternative M2 subunit that is induced by p53 activation in response to DNA damage (56). RRM2B is not cell-cycle regulated per se, but it plays key roles in enhancing dNTP synthesis in cells under stress (120–122) and mediating mtDNA synthesis and repair (57–59).

The role of RNR in cancer is clear as it was one of the first identified DNA damage-induced enzymes (123). While RRM2 overexpression is tumorigenic, leading to lung neoplasms in vivo, RRM1 reduces tumor formation, migration, and metastasis [reviewed in Ref. (53)]. Previous studies from our lab and others have shown the potential of RRM2 as a prognostic and diagnostic biomarker in multiple cancers (112, 124–127). However, the utility of RRM1 and RRM2B as a tumor biomarker is still unclear [reviewed in Ref. (53)].

Although there is no study directly linking RNR with MD, RRM2B is required for mtDNA synthesis and healthy mitochondrial function (57). Deregressed mitochondria are associated with a higher risk of diabetes and obesity (discussed below). Therefore, it is possible that RNR function is linked to these MDs (Table 1). More mechanistic studies will be needed to determine the role for RNR in obesity and diabetes.

### Mitochondrial Dysfunction in dNTP Pool Disruption During Cancer and Metabolic Disease

The mitochondria are one of the most important organelles for eukaryotic function (128). In addition to the production of ATP through oxidative phosphorylation, mitochondria are also the scaffold of several metabolic reactions for cellular building block synthesis (e.g., fatty acid beta-oxidation, one-carbon/folate cycle, TCA cycle, amino acid metabolism, etc.) (129). Hence, altered mitochondrial behavior has a broad impact on cellular metabolism.

Maintenance of mitochondrial dNTP pools is critical for proper mtDNA function. Alterations in nuclear genes involved in transport of cytosolic dNTPs (e.g., SLC25A4), the salvage nucleotide biosynthesis in the inner mitochondrial membrane (e.g., TK2 and DGUOK), and genes involved in mtDNA replication (e.g., TWNK and POLG) are implicated in both cancer and metabolic syndromes (63, 68, 77–79, 130–133). Moreover, dysfunction in the electron transport chain induces oxidative stress, which has been associated with impaired one-carbon metabolism (134, 135), an essential anaplerotic pathway for both purine and pyrimidine nucleotides. Mitochondrial genomic instability due to increased levels of reactive oxygen species (ROS) and/or mutations in mtDNA or nuclear genes involved in mitochondrial function are underlying factors of MDs, and contribute to cancer and diabetes (136). Alterations in genes discussed above that are important for dNTP homeostasis and mitochondrial function are highlighted in Table 1.

Although the link between mitochondrial dysfunction and MD has been studied for the past two decades, the results are contradictory (137). These contradictory results mainly arise from the complex relationship between mitochondria and metabolism, but also from the lack of global and standardized methodological strategies to phenotype insulin-resistance in humans (138). Dysregulation of nucleotide metabolism is an important aspect of mitochondrial dysfunction; therefore, their role in MDs should not be ignored.

### Relationship Between DPPM and Cancer

It is clear that cancer is a metabolic disease; however, a predisposition to cancer is not a foregone conclusion in patients with DPPM, who by definition have alterations in nucleotide supplies. Interestingly, while deficiencies in some metabolic pathways known to play a role in nucleotide synthesis are pro-tumorigenic, others confer an advantage against the onset of cancer. This highlights the large variability in the clinical presentation of these disorders.

Alterations in p53 or ataxia-telangiectasia mutated (ATM) lead to metabolic changes and predispose patients to cancer. Patients with germline TP53 (encoding for p53) mutations have Li–Fraumeni syndrome and are predisposed to cancer (139, 140). Interestingly, a recent report showed that nucleotide metabolism is regulated by the gain-of-function activity of mutant p53 (38). Consistently, wild-type p53 negatively regulates G6PD and PPP activity to decrease dNTP synthesis (37). Similarly, our group has previously shown that ATM (mutated in some ataxia-telangiectasia patients) inactivation increases glucose uptake and enhances glucose flux through the PPP and ultimately increases dNTP biosynthesis (Figure 1) (80, 141). Indeed, patients with ATM mutations show alterations in glucose homeostasis (142, 143). It is well-known that these patients have an increased susceptibility to cancer (144). It is interesting to speculate that alterations in dNTP metabolism may play a role in the cancer predisposition in these patients; however, further studies are needed to support this notion.

Other DPPM confer a tumor suppressive benefit. For instance, patients with G6PD deficiency have a reduced risk of some cancers (145–147) (Table 1). This suggests that hyperactivity of dNTP synthesis is more likely to increase cancer risk than deficiencies in synthesis.

Finally, some DPPM have both a pro- and anti-tumorigenic effect. Deficiency in xanthine oxidoreductase (XOR), the enzyme that catalyzes the last step in purine catabolism (Figure 1), increases UA (148). There is a dual role for UA in cancer, the so-called the oxidant–antioxidant UA paradox (149). On one hand, extracellular UA is a potent ROS scavenger, thus protecting cells against oxidative stress (150). On the other hand, high intracellular levels of UA in a XOR-deficient cellular background promote dNTP biosynthesis and tumor growth by shuttling XOR precursors (xanthine and hypoxanthine) into the purine salvage pathway (149). Additionally, intracellular UA is pro-inflammatory by inducing NADPH-oxidases that lead to oxidative stress and cancer (151, 152). This again emphasizes the complex nature of these disorders in relation to cancer (Table 1).

Together, the lack of consensus in predisposition to cancer in DPPM patients points to the significant redundancy in the dNTP biosynthetic pathways. This should not be surprising due to the fact that dNTP synthesis is critical for organismal survival and, therefore, we have evolved to have multiple metabolic arms feeding into the same pathway. Understanding whether these patients...
are predisposed or not to cancer will be incredibly important for the clinical management of these patients.

THERAPEUTIC MODULATION OF DEOXYRIBONUCLEOTIDE METABOLISM IN CANCER AND METABOLIC DISEASE

As described in this review, the balance of dNTPs must be tightly regulated in the cell. Many cancer types show alterations in dNTP levels, supporting their rapid proliferation. Likewise, defective mutations in anabolic and catabolic nucleotide enzymes, causing imbalances in the dNTP pools or in their precursors, are associated with different grades of disease severity in DPPM. Thus, it is not surprising that therapies for both cancer and DPPM focus on restoration of the normal balance of intracellular nucleotides.

Some of the first chemotherapeutic agents were cytotoxic nucleoside analogs and nucleobases (e.g., thiopurines and fluoropyrimidines) (153). These antimetabolites have a similar molecular structure to endogenous nucleotides and interfere with nucleotide metabolic pathways and DNA/RNA synthesis (154). Inhibitors of RNR were one of the first cancer therapies [reviewed in Ref. (53)] and are still used today. For instance, gemcitabine, a chemotherapeutic nucleoside analog, is used in pancreatic adenocarcinoma, but also in breast, bladder, and non-small cell lung cancer (155). Unfortunately, resistance to gemcitabine will need to focus on mechanistic and population-based studies to determine whether nucleotide pool imbalances in MD lead to changes in cancer predisposition and whether targeting these pathways for cancer therapy affects metabolic homeostasis and function in normal cells.

AUTHOR CONTRIBUTIONS

RB and KA conceived of and wrote the manuscript.

ACKNOWLEDGMENTS

We would like to thank the members of the Aird lab for their thoughtful comments. We would also like to thank Fran Vazquez for help with the dNTP metabolism schematic. RB and KA are supported by an NIH/NCI grant (R00CA194309).

REFERENCES

1. Zeman MK, Cimprich KA. Causes and consequences of replication stress. *Nat Cell Biol* (2014) 16(1):2–9. doi:10.1038/ncb2897
2. Gilkerson R. Commentary: mitochondrial DNA damage and loss in diabetes. *Diabetes Metab Res Rev* (2016) 32:672–4. doi:10.1002/dmr.2833
3. Van Den Berghe G, Vincent MF, Marie S. Disorders of purine and pyrimidine metabolism. In: Saudubray JM, Berge RD, Walter H, editors. *Inborn Metabolic Diseases: Diagnosis and Treatment*. Berlin, Heidelberg: Springer-Verlag (2012). p. 499–518.
4. Mathews CK. DNA precursor metabolism and genomic stability. *FASEB J* (2006) 20:1300–14. doi:10.1096/f.05-5730rev
5. Shimizu I, Yoshida Y, Suda M, Minamino T. DNA damage response and metabolic disease. *Cell Metab* (2014) 20:967–77. doi:10.1016/j.cmet.2014.10.008
6. Kohalmi SE, Glattke M, McIntosh EM, Kunz BA. Mutational specificity of DNA precursor pool imbalances in yeast arising from deoxycytidylate deaminase deficiency or treatment with thymidine. *J Mol Biol* (1991) 220:933–46. doi:10.1006/jmbi.1990.1027
7. Pai CC, Kearsey SE. A critical balance: DNTPs and the maintenance of genome stability. *Genes (Basel)* (2017) 8(2):E57. doi:10.3390/genes8020057
8. Blakley RL, Vitolis E. The control of nucleotide biosynthesis. *Annu Rev Biochem* (1968) 37:201–24. doi:10.1146/annurev.bi.37.070168.001221
9. Lane AN, Fan TW. Regulation of mammalian nucleotide metabolism and biosynthesis. *Nucleic Acids Res* (2015) 43(4):2466–85. doi:10.1093/nar/gkv047
10. Moffatt BA, Ashihara H. Purine and pyrimidine nucleotide synthesis and metabolism. *Arab B* (2002) 1:0018. doi:10.1199/tab.0018
11. Young JD, Yao SYM, Baldwin JM, Cass CE, Baldwin SA. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. *Mol Aspects Med* (2013) 34:529–47. doi:10.1016/j.mam.2012.05.007
12. Fairman JW, Wijerathna SR, Ahmad MF, Xu H, Nakano R, Jha S, et al. Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization. *Nat Struct Mol Biol* (2011) 18:316–22. doi:10.1038/nsmb.2007
13. Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. *Int J Cardiol* (2016) 213:8–14. doi:10.1016/j.ijcard.2015.08.109
14. Westarnack C. Degradation of pyrimidines and pyrimidine analogs-pathways and mutual influences. *Pharmacol Ther* (1980) 8:629–51. doi:10.1016/0163-7258(80)90079-0
15. Van Gennip AH. Defects in metabolism of purines and pyrimidines. *Ned Tijdschr Klin Chem* (1999) 24:171–5.
16. Jurecka A. Inborn errors of purine and pyrimidine metabolism. *J Inherit Metab Dis* (2009) 32:247–63. doi:10.1016/s1054-009-1094-z
Buj and Aird

17. Kohrnik R, Kodigepalli KM, Wu L. Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications. Mol Cancer (2015) 14:176. doi:10.1186/s12943-015-0446-6

18. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab (2016) 23:27–47. doi:10.1016/j.cmet.2015.12.006

19. Bakker JA, Bierau J. Purine and pyrimidine metabolism: still more to learn. Ned Tijdsschr v. Clin Chemie En Lab (2012) 37:3–6.

20. Choi Y-J, Yoon Y, Lee K-Y, Kang Y-P, Lim DK, Kwon SW, et al. Orotic acid (2015) 144:307–17. doi:10.1093/toxicon/kfv003

21. Kunjara S, Sochor M, Ali M, Drake A, Greenbaum AL, McLean P. Pyrimidine nucleotide synthesis in the rat kidney in early diabetes. Biochem Metab Biol Metab (1991) 46:215–25. doi:10.1016/0885-4505(91)90069-W

25. Jo YS, Oh HR, Kim MS, Yoo NJ, Lee SH. Frameshift mutations of OGDH, its gain-of-function activities. Nature (2000) 403:328–32. doi:10.1038/3500211

26. Le TT, Ziemba A, Urasaki Y, Hayes E, Brotman S, Pizzorno G. Disruption of mitochondrial DNA susceptibility loci. Frontiers in Endocrinology (2014) 5:100. doi:10.3389/fendo.2014.00100

27. Pillwein K, Reardon MA, Jayaram HN, Natsumeda Y, Elliott WL, Faderan MA, et al. Distinct high resolution genome profiles of early onset and late onset type 2 diabetes: potential role of p38 in the downregulation of GLUT4 expression. Diabetes (2003) 52:634–41. doi:10.2337/diabetes.52.5.634

28. Cornu M, Albert V, Hall MN. MTOR in aging, metabolism, and cancer. J Biol Chem (2013) 288:27138–49. doi:10.1074/jbc.M113.485094

29. Burotto M, Chiou VL, Lee J-M, Kohn EC. The MAPK pathway across ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. Cell.2012.03.003

30. Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo nucleotide biosynthesis in cancer cells. Cell Metab (2009) 19(1):32–7. doi:10.1016/j.cmet.2009.01.002

31. Mackenzie RW, Elliott BT. Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes (2014) 7:55–64. doi:10.2147/DMSO.S458260

32. Matsuda S, Kobayashi M, Kitagishi Y. Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease. ISRN Endocrinol (2013) 2013:472432. doi:10.1155/2013/472432

33. Izumiya Y, Hopkins T, Morris C, Sato K, Zeng L, Viercek J, et al. Fast glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab (2008) 7:159–72. doi:10.1016/J.CCMET.2007.11.003

34. Graves LM, Guy HI, Kozlowski P, Huang M, Lazarowski E, Pope RM, et al. Regulation of carbamoyl phosphate synthetase by MAP kinase. Nature (2000) 403:328–32. doi:10.1038/3500211

35. Murata T, Chiu VL, Lee J-M, Kohn EC. The MAPK pathway across ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. Cell.2012.03.003

36. Bost F, Aouadi M, Caron L, Binétruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie (2005) 87:51–6. doi:10.1016/J.BIOCHEL.2004.10.018

37. Drukker M, De Gregorio E, Kussie P, Zhang E, Intemann T, Armington S, et al. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nat Commun (2015) 6:7389. doi:10.1038/ncomms8389

38. Liu J, Zhang C, Feng Z. Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim Biophys Sin (Shanghai) (2014) 46(3):170–9. doi:10.1093/abbs/gmt144

39. Yang P-Y, Ma W, Park J-Y, Celis F, Arena R, Choi JW, et al. Increased oxidative metabolism in the Li-Fraumeni syndrome. N Engl J Med (2013) 368:1027–32. doi:10.1056/NEJMoa124091

40. Tong X, Zhao F, Thompson CB. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev (2009) 19(1):32–7. doi:10.1016/j.gde.2009.01.002

41. Kim TH, Yoon Y, Lee K-Y, Kang Y-P, Lim DK, Kwon SW, et al. Orotic acid (2015) 144:307–17. doi:10.1093/toxicon/kfv003

42. Bakker JA, Bierau J. Purine and pyrimidine metabolism: still more to learn. Ned Tijdsschr v. Clin Chemie En Lab (2012) 37:3–6.

43. Kohnken R, Kodigepalli KM, Wu L. Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications. Mol Cancer (2015) 14:176. doi:10.1186/s12943-015-0446-6

44. Izumiya Y, Hopkins T, Morris C, Sato K, Zeng L, Viercek J, et al. Fast glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab (2008) 7:159–72. doi:10.1016/J.CCMET.2007.11.003

45. Graves LM, Guy HI, Kozlowski P, Huang M, Lazarowski E, Pope RM, et al. Regulation of carbamoyl phosphate synthetase by MAP kinase. Nature (2000) 403:328–32. doi:10.1038/3500211

46. Burotto M, Chiou VL, Lee J-M, Kohn EC. The MAPK pathway across ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. Cell.2012.03.003

47. Bost F, Aouadi M, Caron L, Binétruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie (2005) 87:51–6. doi:10.1016/J.BIOCHEL.2004.10.018

48. Bost F, Aouadi M, Caron L, Binétruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie (2005) 87:51–6. doi:10.1016/J.BIOCHEL.2004.10.018

49. Bost F, Aouadi M, Caron L, Binétruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie (2005) 87:51–6. doi:10.1016/J.BIOCHEL.2004.10.018

50. Fost J, Aoudai M, Caron L, Binétruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie (2005) 87:51–6. doi:10.1016/J.BIOCHEL.2004.10.018

51. Bost F, Aouadi M, Caron L, Binétruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie (2005) 87:51–6. doi:10.1016/J.BIOCHEL.2004.10.018

52. Bost F, Aouadi M, Caron L, Binétruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie (2005) 87:51–6. doi:10.1016/J.BIOCHEL.2004.10.018

53. Bost F, Aouadi M, Caron L, Binétruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie (2005) 87:51–6. doi:10.1016/J.BIOCHEL.2004.10.018

54. Bost F, Aouadi M, Caron L, Binétruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie (2005) 87:51–6. doi:10.1016/J.BIOCHEL.2004.10.018

55. Bost F, Aouadi M, Caron L, Binétruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie (2005) 87:51–6. doi:10.1016/J.BIOCHEL.2004.10.018

56. Bost F, Aouadi M, Caron L, Binétruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie (2005) 87:51–6. doi:10.1016/J.BIOCHEL.2004.10.018
113. Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M, et al. Nucleotide
112. Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, et al. Suppression
111. Dann SG, Selvaraj A, Thomas G. mTOR complex1-S6K1 signaling: at
110. Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer
107. Xia J-F, Liang Q-L, Liang X-P, Wang Y-M, Hu P, Li P, et al. Ultraviolet and
105. Ham M, Choe SS, Shin KC, Choi G, Kim JW, Noh JR, et al. Glucose-6-
Buj and Aird
108. Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent
106. Hofer A, Crona M, Logan DT, Sjöberg BM. DNA building blocks: keeping
104. McKinnon PJ. ATM and ataxia telangiectasia.
137. Montgomery MK, Turner N. Mitochondrial dysfunction and insulin resis-
135. Nikkanen J, Forsström S, Euro L, Paetau I, Kohnz RA, Wang L, et al. Mitochondrial DNA copy number is regulated by DNA methylation and demethylation of POLCA subunits M2 and p53R2 in cancer tissues and cancer cells and their differentiated progeny.
134. Zhou X, Kannisto K, Curbo S, von Dobeln U, Hultenby K, Isetun S, et al. Thymidine kinase 2 deficiency-induced mtDNA depletion in mouse liver leads to defect beta-oxidation.
133. Zhou X, Kannisto K, Curbo S, von Dobeln U, Hultenby K, Isetun S, et al. Thymidine kinase 2 deficiency-induced mtDNA depletion in mouse liver leads to defect beta-oxidation.
132. Gandhi VV, Samuels DC. Correlated tissue expression of genes of cytoplasmic and mitochondrial nucleotide metabolisms in normal tissues is disrupted in transformed tissues. Nucleosides Nucleotides Nucleic Acids (2012) 31:112–29.
131. Hirano M, DiMauro S. Mitochondrial myopathies. Adv Neurol (2002) 88:217–34.
130. Gandhi VV, Samuels DC. Correlated tissue expression of genes of cytoplasmic and mitochondrial nucleotide metabolisms in normal tissues is disrupted in transformed tissues. Nucleosides Nucleotides Nucleic Acids (2012) 31:112–29.
129. Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Mitochondrial control of cellular life, stress, and death. Circ Res (2012) 111(9):1198–207. doi: 10.1161/CIRCRESAHA.112.268946
128. Eriksson S, Graslund A, Skog S, Thelander L, Tribukait B. Cell cycle-depen-
127. Galldrup M, Moreau P, Dore MP, Davoli A, Longo N, Marras G, Pes GM, et al. Mitochondrial dysfunction remodels one-carbon metabolism in human cells. Elife (2016) 5:e10575. doi:10.7554/eLife.10575
126. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, et al. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia (2010) 12:807–17. doi:10.1593/neo.10458
125. Dressman HK, Hans C, Bild A, Olson JA, Rosen E, Marcom PK, et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res (2006) 12:819–26. doi:10.1158/1078-0432.CCR-05-0482
124. Aird KM, Li H, Xin F, Konstantinopoulos PA, Zhang R. Identification of ribonucleotide reductase subunit M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Color Cancer Res (2007) 6:374–81. doi:10.1158/1541-7786.MCR-07-0007
123. Dolecek TA, Stovall M, Coates AS, Piantadosi S, Todo Y, Atwood WJ, et al. The influence of radiation on breast cancer mortality. Cancer (1989) 63:2106–14. doi:10.1002/cncr.2820630733
122. Dinsmore L, Lipman B, Folland R, Hall M, Reichard P. CD44v6 expression in human cancer: correlation with tumor metastatic potential and survival in patients with primary pancreatic adenocarcinoma. Am J Surg Pathol (2003) 27:137–43. doi:10.1097/01.PAS.0000047345.90443.59
121. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet (2004) 36:75–9. doi:10.1038/ng.983
120. Dahl ES, Aird KM. Ataxia-telangiectasia mutated modulation of carbon metabolism in cancer. Front Oncol (2017) 7:291. doi:10.3389/fonc.2017.00291
119. Bar RS, Levis WR, Rechler MM, Harrison LC, Siebert C, Podskalny J, et al. Extreme insulin resistance in ataxia telangiectasia: defect in affinity of insulin receptors. N Engl J Med (1978) 298:1164–71. doi:10.1056/NEJM197805252982103
118. Eriksson S, Graslund A, Skog S, Thelander L, Tribukait B. DNA building blocks: keeping control of manufacture. Crit Rev Biochem Mol Biol (2012) 47(1):50–63. doi:10.1080/10409238.2011.630372
117. Nordlund P, Reichard P. Ribonucleotide reductases. Annu Rev Biochem (2006) 75:681–706. doi:10.1146/annurev.biochem.75.103004.142443
116. Erikkson S, Graslund A, Skog S, Thelander L, Tribukait B. Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis. J Biol Chem (1984) 259:11695–700.
115. D’Angioleva L, Donato V, Forrester FM, Jeong YT, Pellacani C, Kudo Y, et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell (2012) 149:1023–34. doi:10.1016/j.cell.2012.03.043
114. Fskoloupi IP, Jorgensen C, Leszczynska KB, Olcina MM, Tarhonskaya H, Haisma B, et al. Ribonucleotide reductase requires subunit switching in hypoxia to maintain DNA replication. Mol Cell (2017) 66:220–39. doi:10.1016/j.molcel.2017.03.005
113. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet (2003) 33:440–5. doi:10.1038/ng1212
112. Liu X, Xue L, Yen Y. Redox property of ribonucleotide reductase small subunit M2 and p53R2. Methods Mol Biol (2008) 477:195–206. doi:10.1007/978-1-60327-517-0_15
111. Elledge SJ, Zhou Z, Allen JB, Navas TA. DNA damage and cell cycle regulation of ribonucleotide reductase. Bioessays (1993) 15:333–9. doi:10.1002/bies.990500567
110. Aird KM, Li H, Xin F, Konstantinopoulos PA, Zhang R. Identification of ribonucleotide reductase M2 as a potential target for pro-senesence therapy in epithelial ovarian cancer. Cell Cycle (2014) 13:199–207. doi:10.4161/cc.26953
109. Ham M, Choe SS, Choi G, Kim JW, Noh JR, et al. Glucose-6-phosphate dehydrogenase deficiency improves insulin resistance with reduced adipose tissue inflammation in obesity. Diabetes (2016) 65:6264–38. doi:10.2337/db16-0086
108. Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev (2016) 17:510–9. doi:10.1111/obr.12407
107. Xia J-F, Liang Q-L, Liang X-P, Wang Y-M, Hu P, Li P, et al. Ultraviolet and cancer-related mortality. Physiol Rev (2015) 95:727–48. doi:10.1152/physrev.00030.2014
106. Dore MP, Davoli A, Longo N, Marras G, Pes GM. Glucose-6-phosphate dehydrogenase deficiency and risk of colorectal cancer in Northern Sardinia: a retrospective observational study. Medicine (Baltimore) (2016) 95:e5254. doi:10.1097/MD.0000000000005254
105. Ham M, Choe SS, Shin KC, Choi G, Kim JW, Noh JR, et al. Glucose-6-phosphate dehydrogenase deficiency and consanguinity in Sardinia: a spatial
correlation analysis. Asian Pac J Cancer Prev (2017) 18:2403–7. doi:10.22034/APJCP.2017.18.9.2403

148. Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med (2012) 1:16. doi:10.1186/2001-1326-1-16

149. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids (2008) 27(6):608–19. doi:10.1080/1525770802138558

150. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact (2006) 160(1):1–40. doi:10.1016/j.cbi.2005.12.009

151. Lu W, Xu Y, Shao X, Gao F, Li Y, Hu J, et al. Uric acid produces an inflammatory response through activation of NF-κB in the hypothalamus: implications for the pathogenesis of metabolic disorders. Sci Rep (2015) 5. doi:10.1038/srep12144

152. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 49(11):1603–16. doi:10.1016/j.freeradbiomed.2010.09.006

153. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol (2002) 3(7):415–24. doi:10.1016/S1470-2245(02)00788-X

154. Muñoz-Pinedo C, El Mjiyad N, Ricci J-E. Cancer metabolism: current perspectives and future directions. Cell Death Dis (2012) 3:e248. doi:10.1038/cddis.2011.123

155. de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol (2014) 741:8–16. doi:10.1016/j.ejphar.2014.07.041

156. Amrutkar M, Gladhaug IP. Pancreatic cancer chemoresistance to gemcitabine. Cancers (Basel) (2017) 9. doi:10.3390/cancers9110157

157. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv (2016) 2(5):e1600200. doi:10.1126/sciadv.1600200

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.